Immunology of multiple sclerosis

Annual Review of Immunology

Volumn 23, Issue , 2005, Pages 683-747

  Sospedra, Mireia ^a   Martin, Roland ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Autoimmune mechanisms; Autoimmunity; Demyelinating dieseases; EAE; Neuroimmunology

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; ALPHA CRYSTALLIN; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CLADRIBINE; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOKINE; DACLIZUMAB; DNA VACCINE; GLATIRAMER; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; NATALIZUMAB; NITRIC OXIDE SYNTHASE; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN S100B; ROLIPRAM; TOLL LIKE RECEPTOR; TRANSALDOLASE;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; BYSTANDER EFFECT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMPLEMENT SYSTEM; DISEASE COURSE; FLU LIKE SYNDROME; GENETIC TRAIT; HLA SYSTEM; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MAST CELL; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUROIMMUNOLOGY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VIRUS INFECTION;

AUTOANTIBODIES; AUTOANTIGENS; CENTRAL NERVOUS SYSTEM; CHEMOKINES; CYTOKINES; GENOMICS; HLA ANTIGENS; HUMANS; IMMUNITY, NATURAL; IMMUNOGENETICS; INFECTION; MODELS, IMMUNOLOGICAL; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; MYELIN PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 17644396349     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.23.021704.115707     Document Type: Review

References (359)

1. McFarlin DE, McFarland HF. 1982. Multiple sclerosis (first of two parts). N. Engl. J. Med. 307:1183-88
2. McFarlin DE, McFarland HF. 1982. Multiple sclerosis (second of two parts). N. Engl. J. Med. 307:1246-51
3. McFarland HF. 1999. Correlation between MR and clinical findings of disease activity in multiple sclerosis. Am. J. Neuroradiol. 20:1777-78
4. Raine CS, Scheinberg LC. 1988. On the immunopathology of plaque development and repair in multiple sclerosis. J. Neuroimmunol. 20:189-201
5. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:707-17
6. Martin R, McFarland HF, McFarlin DE. 1992. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:153-87
7. Hafler DA. 2004. Multiple sclerosis. J. Clin. Invest. 113:788-94
8. Zamvil SS, Steinman L. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8:579-621
9. + 2-T lymphocytes. J. Immunol. 127:1420-23
10. + T cells in a model for multiple sclerosis. J. Exp. Med. 194:669-76
11. + T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 166:7579-87
12. Pitt D, Werner P, Raine CS. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6:67-70
13. John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, et al. 2002. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat. Med. 8:1115-21
14. Dyment DA, Ebers GC, Sadovnick AD. 2004. Genetics of multiple sclerosis. Lancet Neurol. 3:104-10
15. Haines JL, Bradford Y, Garcia ME, Reed AD, Neumeister E, et al. 2002. Multiple susceptibility loci for multiple sclerosis. Hum. Mol. Genet. 11:2251-56
16. Ebers GC, Sadovnick AD, Risch NJ. 1995. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377:150-51
17. GAMES, Transatlantic Multiple Sclerosis Genetics Cooperative. 2003. A meta-analysis of whole genome linkage screens in multiple sclerosis. J. Neuroimmunol. 143:39-46
18. Hillert J, Olerup O. 1993. HLA and MS. Neurology 43:2426-27
19. Haines JL, Terwedow HA, Burgess K, Pericak-Vance MA, Rimmler JB, et al. 1998. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum. Mol. Genet. 7:1229-34
20. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, et al. 2003. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72:710-16
21. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. 2000. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 55:140-48
22. Fernandez O, Fernandez V, Alonso A, Caballero A, Luque G, et al. 2004. DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J. Neurol. 251:440-44
23. Bertram J, Kuwert E. 1982. HLA antigen frequencies in multiple sclerosis. Eur. J. Neurol. 7:74-79
24. Sellebjerg F, Jensen J, Madsen HO, Svejgaard A. 2000. HLA DRB1*1501 and intrathecal inflammation in multiple sclerosis. Tissue Antigens 55:312-18
25. Ridgway WM, Ito H, Fasso M, Yu C, Fathman CG. 1998. Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell response. J. Exp. Med. 188:2267-75
26. Merryman PF, Crapper RM, Lee S, Gregersen PK, Winchester RJ. 1989. Class II major histocompatibility complex gene sequences in rheumatoid arthritis. The third diversity regions of both DRβ1 genes in two DR1, DRw10-positive individuals specify the same inferred amino acid sequence as the DRβ1 and DRβ2 genes of a DR4 (Dw14) haplotype. Arthritis Rheum. 32:251-58
27. Ristori G, Carcassi C, Lai S, Fiori P, Cacciani A, et al. 1997. HLA-DM polymorphisms do not associate with multiple sclerosis: an association study with analysis of myelin basic protein T cell specificity. J. Neuroimmunol. 77:181-84
28. Matsuoka T, Tabata H, Matsushita S. 2001. Monocytes are differentially activated through HLA-DR, -DQ, and -DP molecules via mitogen-activated protein kinases. J. Immunol. 166:2202-8
29. Li F, Linan MJ, Stein MC, Faustman DL. 1995. Reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes. Ann. Neurol. 38:147-54
30. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192:393-404
31. + T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125:538-50
32. Head JR, Griffin WST. 1985. Functional capacity of solid tissue transplants in brain: evidence for immonological privilege. Proc. R. Soc. London Ser. B 224:375-87
33. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, et al. 1996. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14:457-60
34. Whitney LW, Becker KG, Tresser NJ, Caballero-Ramos CI, Munson PJ, et al. 1999. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 46:425-28
35. Whitney LW, Ludwin SK, McFarland HF, Biddison WE. 2001. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Neuroimmunol. 121:40-48
36. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-8
37. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AE, Nagra RM, et al. 2003. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res. Mol. Brain Res. 119:170-83
38. Mycko MP, Papoian R, Beschert U, Raine CS, Selmaj KW. 2004. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin. Neurol. Neurosurg. 106:223-29
39. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, et al. 2000. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J. Immunol. 165:6576-82
40. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, et al. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-35
41. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. 2003. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 13:554-73
42. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. 2004. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. 55:410-17
43. Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, et al. 2003. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 12:2191-99
44. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, et al. 2001. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50:349-57
45. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, et al. 2003. Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain 126:1419-29
46. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, et al. 2003. TNF-related apoptosis inducing Hg- and (TRAIL) as a potential response marker for interferon-β treatment in multiple sclerosis. Lancet 361:2036-43
47. McFarland HF. 1992. Twin studies and multiple sclerosis. Ann. Neurol. 32:722-23
48. Wakeland EK, Liu K, Graham RR, Behrens TW. 2001. Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397-408
49. Coo H, Aronson KJ. 2004. A systematic review of several potential non-genetic risk factors for multiple sclerosis. Neuroepidemiology 23:1-12
50. Runmarker B, Andersen O. 1995. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118(Part 1):253-61
51. Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, et al. 2002. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52:421-28
52. Kurtzke JF. 1983. Epidemiology of multiple sclerosis. In Multiple Sclerosis, ed. JF Hallpike, CWM Adams, WW Tourtelotte, pp. 49-95. Baltimore, MD: Williams & Wilkins
53. Hayes CE. 2000. Vitamin D: a natural inhibitor of multiple sclerosis. Proc. Nutr. Soc. 59:531-35
54. Johnson RT. 1994. The virology of demyelinating diseases. Ann. Neurol. 36(Suppl.):S54-60
55. Soldan SS, Jacobson S. 2001. Role of viruses in etiology and pathogenesis of multiple sclerosis. Adv. Virus Res. 56:517-55
56. Sibley WA, Bamford CR, Clark K. 1985. Clinical viral infections and multiple sclerosis. Lancet 1:1313-15
57. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72:551-60
58. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, et al. 1995. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc. Natl. Acad. Sci. USA 92:7440-44
59. Moore FG, Wolfson C. 2002. Human herpes virus 6 and multiple sclerosis. Acta Neurol. Scand. 106:63-83
60. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S. 2000. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann. Neurol. 47:306-13
61. Wandinger KP, Jabs W, Siekhaus A, Bubel S, Trillenberg P, et al. 2000. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 55:178-84
62. Martyn CN, Cruddas M, Compston DA. 1993. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 56:167-68
63. Sriram S, Mitchell W, Stratton C. 1998. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 50:571-72
64. Sriram S, Stratton CW, Yao S, Tharp A, Ding L, et al. 1999. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann. Neurol. 46:6-14
65. Pucci E, Taus C, Cartechini E, Morelli M, Giuliani G, et al. 2000. Lack of Chlamydia infection of the central nervous system in multiple sclerosis. Ann. Neurol. 48:399-400
66. Burns J, Rosenzweig A, Zweiman B, Lisak RP. 1983. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol. 81:435-40
67. Richert JR, McFarlin DE, Rose JW, McFarland HF, Greenstein JI. 1983. Expansion of antigen-specific T cells from cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 5:317-24
68. Chou YK, Vainiene M, Whitham R, Bourdette D, Chou CH, et al. 1989. Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA class II restriction molecules. J. Neurosci. Res. 23:207-16
69. Martin R, Jaraquemada D, Flerlage M, Richert J, Whitaker J, et al. 1990. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145:540-48
70. Pette M, Fujita K, Kitze B, Whitaker JN, Albert E, et al. 1990. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40:1770-76
71. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. 1990. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346:183-87
72. Olsson T, Zhi WW, Hojeberg B, Kostulas V, Jiang YP, et al. 1990. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ. J. Clin. Invest. 86:981-85
73. Fujinami RS, Oldstone MB. 1985. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230:1043-45
74. Tejada-Simon MV, Zang YCQ, Hong J, Rivera VM, Zhang JWZ. 2003. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann. Neurol. 53:189-97
75. Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM. 1993. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J. Immunol. 150:3131-40
76. Wucherpfennig KW, Strominger JL. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705
77. Hemmer B, Vergelli M, Gran B, Ling N, Conlon P, et al. 1998. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J. Immunol. 160:3631-36
78. Hemmer B, Pinilla C, Gran B, Vergelli M, Ling N, et al. 2000. Contribution of individual amino acids within MHC molecule or antigenic peptide to TCR ligand potency. J. Immunol. 164:861-71
79. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, et al. 2002. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3:940-43
80. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, et al. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305-17
81. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65:319-31
82. Olson JK, Croxford JL, Miller SD. 2004. Innate and adaptive immune requirements for induction of autoimmune demyelinating disease by molecular mimicry. Mol. Immunol. 40:1103-8
83. Tough DF, Sprent J. 1996. Viruses and T cell turnover: evidence for bystander proliferation. Immunol. Rev. 150:129-42
84. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, et al. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-87
85. Brocke S, Gaur A, Piercy C, Gautam A, Gijbels K, et al. 1993. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 365:642-44
86. Waldner H, Collins M, Kuchroo VK. 2004. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113:990-97
87. Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, et al. 1997. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3:1133-36
88. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. 1998. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med. 4:781-85
89. Barnaba V. 1996. Viruses, hidden self-epitopes and autoimmunity. Immunol. Rev. 152:47-66
90. Opdenakker G, Van Damme J. 1994. Cytokine-regulated proteases in autoimmune diseases. Immunol. Today 15:103-7
91. Pender MP. 2003. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 24:584-88
92. Charcot J. 1868. Histologie de la sclerose en plaque. Gaz. Hopitaux 41:554-66
93. Remlinger J. 1905. Accidents paralytiques au cours du traitment antirabique. Ann. Inst. Pasteur 19:625-46
94. Rivers TM, Sprunt DH, Berry GP. 1933. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 58:39-53
95. Ben-Nun A, Cohen IR. 1982. Experimental autoimmune encephalomyelitis (EAE) mediated by T cell lines: process of selection of lines and characterization of the cells. J. Immunol. 129:303-8
96. Das P, Drescher KM, Geluk A, Bradley DS, Rodriguez M, David CS. 2000. Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Hum. Immunol. 61:279-89
97. Kawamura K, Yamamura T, Yokoyama K, Chui DH, Fukui Y, et al. 2000. HLA-DR2-restricted responses to proteolipid protein 95-116 peptide cause autoimmune encephalitis in transgenic mice. J. Clin. Invest. 105:977-84
98. Forsthuber TG, Shive CL, Wienhold W, deGraaf K, Spack EG, et al. 2001. T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells. J. Immunol. 167:7119-25
99. Madsen LS, Andersson EC, Jansson L, Krogsgaard M, Andersen CB, et al. 1999. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23:343-47
100. Quandt JA, Baig M, Yao K, Kawamura K, Huh J, et al. 2004. Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized transgenic mice. J. Exp. Med. 200:223-34
101. Bielekova B, Goodwin B, Riehen N, Cortese I, Kondo T, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:1167-75
102. Berger T, Weerth S, Kojima K, Linington C, Wekerle H, Lassmann H. 1997. Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab. Invest. 76:355-64
103. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. 1994. Animal models. Ann. Neurol. 36:847-53
104. Schluesener HJ, Wekerle H. 1985. Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations. J. Immunol. 135:3128-33
105. Martin R, Voskuhl R, Flerlage M, McFarlin DE, McFarland HF. 1993. Myelin basic protein-specific T-cell responses in identical twins discordant or concordant for multiple sclerosis. Ann. Neurol. 34:524-35
106. Bieganowska KD, Ausubel LJ, Modabber Y, Slovik E, Messersmith W, Hafler DA. 1997. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 185:1585-94
107. Muraro PA, Wandinger KP, Bielekova B, Gran B, Marques A, et al. 2003. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 126:20-31
108. + T cells in multiple sclerosis. J. Immunol. 172:3893-904
109. Hong J, Zang YCQ, Li SF, Rivera VM, Zhang JWZ. 2004. Ex vivo detection of myelin basic protein-reactive T cells in multiple sclerosis and controls using specific TCR oligonucleotide probes. Eur. J. Immunol. 34:870-81
110. + T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103:4222-31
111. Olsson T, Sun J, Hillert J, Hojeberg B, Ekre HP, et al. 1992. Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur. J. Immunol. 22:1083-87
112. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. 1990. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247:718-21
113. Trotter JL, Damico CA, Cross AH, Pelfrey CM, Karr RW, et al. 1997. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J. Neuroimmunol. 75:95-103
114. Seamons A, Perchellet A, Goverman J. 2003. Immune tolerance to myelin proteins. Immunol. Res. 28:201-21
115. Bruno R, Sabater L, Sospedra M, Ferrer-Francesch X, Escudero D, et al. 2002. Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus. Eur. J. Immunol. 32:2737-47
116. Pette M, Fujita K, Wilkinson D, Altmann DM, Trowsdale J, et al. 1990. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc. Natl. Acad. Sci. USA 87:7968-72
117. Martin R, Howell MD, Jaraquemada D, Flerlage M, Richert J, et al. 1991. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J. Exp. Med. 173:19-24
118. Valli A, Sette A, Kappos L, Oseroff C, Sidney J, et al. 1993. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J. Clin. Invest. 91:616-28
119. Wucherpfennig KW, Sette A, Southwood S, Oseroff C, Matsui M, et al. 1994. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179:279-90
120. Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee HG, et al. 1994. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 153:1665-73
121. Muraro PA, Vergelli M, Kalbus M, Banks DE, Nagle JW, et al. 1997. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. J. Clin. Invest. 100:339-49
122. Vergelli M, Kalbus M, Rojo SC, Hemmer B, Kalbacher H, et al. 1997. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. J. Neuroimmunol. 77:195-203
123. Richert JR, Robinson ED, Deibler GE, Martenson RE, Dragovic LJ, Kies MW. 1989. Human cytotoxic T-cell recognition of a synthetic peptide of myelin basic protein. Ann. Neurol. 26:342-46
124. Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. 1989. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 59:247-55
125. Fairchild PJ, Wraith DC. 1992. Peptide-MHC interaction in autoimmunity. Curr. Opin. Immunol. 4:748-53
126. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. 1994. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 78:399-408
127. Krogsgaard M, Wucherpfennig KW, Cannella B, Hansen BE, Svejgaard A, et al. 2000. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191:1395-412
128. Klein L, Klugmann M, Nave K-A, Tuohy VK, Kyewski B. 2000. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat. Med. 6:56-62
129. Waldner H, Whitters MJ, Sobel RA, Collins M, Kuchroo VK. 2000. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc. Natl. Acad. Sci. USA 97:3412-17
130. Kennedy MK, Tan LJ, Dal Canto MC, Tuohy VK, Lu ZJ, et al. 1990. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 144:909-15
131. Vanderlugt CL, Miller SD. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2:85-95
132. Correale J, McMillan M, McCarthy K, Le T, Weiner LP. 1995. Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients. Neurology 45:1370-78
133. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. 1997. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120(Part 8):1447-60
134. + T cells from multiple sclerosis patients. J. Neuroimmunol. 46:33-42
135. + T cells from multiple sclerosis patients. J. Neuroimmunol. 53:153-61
136. Kondo T, Yamamura T, Inobe J, Ohashi T, Takahashi K, Tabira T. 1996. TCR repertoire to proteolipid protein (PLP) in multiple sclerosis (MS): homologies between PLP-specific T cells and MS-associated T cells in TCR junctional sequences. Int. Immunol. 8:123-30
137. Mendel I, Kerlero de Rosbo N, Ben-Nun A. 1995. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells. Eur. J. Immunol. 25:1951-59
138. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. 2003. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 197:1073-81
139. Tsunoda I, Kuang LQ, Theil DJ, Fujinami RS. 2000. Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. Brain Pathol. 10:402-18
140. Kerlero de Rosbo N, Hoffman M, Mendel I, Yust I, Kaye J, et al. 1997. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur. J. Immunol. 27:3059-69
141. + multiple sclerosis. Eur. J. Immunol. 28:3329-35
142. Koehler NK, Genain CP, Giesser B, Hauser SL. 2002. The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. J. Immunol. 168:5920-27
143. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. 2001. T- and B-cell responses to myelin oligodendrocyte gly coprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36:220-34
144. Weissert R, Kuhle J, de Graaf KL, Wienhold W, Herrmann MM, et al. 2002. High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes. J. Immunol. 169:548-56
145. Lindert RB, Haase CG, Brehm U, Linington C, Wekerle H, Hohlfeld R. 1999. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 122(Part 11):2089-100
146. Steck AJ, Murray N, Meier C, Page N, Perruisseau G. 1983. Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology 33:19-23
147. Morris-Downes MM, McCormack K, Baker D, Sivaprasad D, Natkunarajah J, Amor S. 2002. Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in ABH and SJL mice. J. Neuroimmunol. 122:20-33
148. Andersson M, Yu M, Soderstrom M, Weerth S, Baig S, et al. 2002. Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. Eur. J. Neurol. 9:243-51
149. Birnbaum G, Kotilinek L, Schlievert P, Clark HB, Trotter J, et al. 1996. Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2′,3′ cyclic nucleotide 3′ phosphodiesterase that is cross-reactive with a heat shock protein alters the course of EAE. J. Neurosci. Res. 44:381-96
150. Rosener M, Muraro PA, Riethmuller A, Kaibus M, Sappler G, et al. 1997. 2′,3′-cyclic nucleotide 3′-phosphodiesterase: a novel candidate autoantigen in demyelinating diseases. J. Neuroimmunol. 75:28-34
151. Muraro PA, Kaibus M, Afshar G, McFarland HF, Martin R. 2002. T cell response to 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in multiple sclerosis patients. J. Neuroimmunol. 130:233-42
152. Holz A, Bielekova B, Martin R, Oldstone MB. 2000. Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis. J. Immunol. 164:1103-9
153. Kaye JF, Kerlero de Rosbo N, Mendel I, Flechter S, Hoffman M, et al. 2000. The central nervous sytem-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS). J. Neuroimmunol. 102:189-98
154. Arbour N, Holz A, Sipe JC, Naniche D, Romine JS, et al. 2003. A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis. J. Neuroimmunol. 137:197-209
155. Bronstein JM, Lallone RL, Seitz RS, Ellison GW, Myers LW. 1999. A humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic. Neurology 53:154-61
156. Vu T, Myers LW, Ellison GW, Mendoza F, Bronstein JM. 2001. T-cell responses to oligodendrocyte-specific protein in multiple sclerosis. J. Neurosci. Res. 66:506-9
157. van Noort JM, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, et al. 1995. The small heat-shock protein αB-crystallin as candidate autoantigen in multiple sclerosis. Nature 375:798-801
158. Chou YK, Burrows GG, LaTocha D, Wang C, Subramanian S, et al. 2004. CD4 T-cell epitopes of human αB-crystallin. J. Neurosci. Res. 75:516-23
159. Saez-Torres I, Brieva L, Espejo C, Barrau MA, Montalban X, Martinez-Caceres EM. 2002. Specific proliferation towards myelin antigens in patients with multiple sclerosis during a relapse. Autoimmunity 35:45-50
160. Kojima K, Berger T, Lassmann H, Hinze-Selch D, Zhang Y, et al. 1994. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100β molecule, a calcium binding protein of astroglia. J. Exp. Med. 180:817-29
161. Schmidt S, Linington C, Zipp F, Sotgiu S, de Waal Malefyt R, et al. 1997. Multiple sclerosis: comparison of the human T-cell response to S100β and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain 120(Part 8):1437-45
162. Banki K, Colombo E, Sia F, Halladay D, Mattson DH, et al. 1994. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J. Exp. Med. 180:1649-63
163. Colombo E, Banki K, Tatum AH, Daucher J, Ferrante P, et al. 1997. Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. J. Clin. Invest. 99:1238-50
164. Holmoy T, Vandvik B, Vartdal F. 2003. T cells from multiple sclerosis patients recognize immunoglobulin G from cerebrospinal fluid. Mult. Scler. 9:228-34
165. Holmoy T, Vartdal F. 2004. Cerebrospinal fluid T cells from multiple
166. Sadatipour BT, Greer JM, Pender MP. 1998. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann. Neurol. 44:980-83
167. Pender MP, Csurhes PA, Wolfe NP, Hooper KD, Good MF, et al. 2003. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J. Clin. Neurosci. 10:63-66
168. Meinl E, Weber F, Drexler K, Morelle C, Ott M, et al. 1993. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J. Clin. Invest. 92:2633-43
169. Hemmer B, Fleckenstein BT, Vergelli M, Jung G, McFarland H, et al. 1997. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J. Exp. Med. 185:1651-59
170. Zhao Y, Gran B, Pinilla C, Markovic-Plese S, Hemmer B, et al. 2001. Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J. Immunol. 167:2130-41
171. Jaraquemada D, Martin R, Rosen-Bronson S, Flerlage M, McFarland HF, Long EO. 1990. HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. J. Immunol. 145:2880-85
172. Minohara M, Ochi H, Matsushita S, Irie A, Nishimura Y, Kira J. 2001. Differences between T-cell reactivities to major myelin protein-derived peptides in opticospinal and conventional forms of multiple sclerosis and healthy controls. Tissue Antigens 57:447-56
173. Yu M, Kinkel RP, Weinstock-Guttman B, Cook DJ, Tuohy VK. 1998. HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. Hum. Immunol. 59:15-24
174. Hemmer B, Vergelli M, Calabresi P, Huang T, McFarland HF, Martin R. 1996. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). J. Neurosci. Res. 45:852-62
175. Correale J, Gilmore W, McMillan M, Li S, McCarthy K, et al. 1995. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 154:2959-68
176. + T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 94:599-603
177. + T cells via CD40-CD40 ligand interactions. J. Neuroimmunol. 125:134-40
178. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, et al. 2002. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415:536-41
179. Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, et al. 2004. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J. Immunol. 172:7169-76
180. + myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. J. Immunol. 157:679-88
181. + T cell clones use perform- or Fas/Fas ligand-mediated pathways for target cell lysis. J. Immunol. 158:2756-61
182. Antel JP, McCrea E, Ladiwala U, Qin YF, Becher B. 1998. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J. Immunol. 160:1606-11
183. Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. 1998. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J. Immunol. 160:1532-38
184. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. 1998. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 101:725-30
185. - costimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 108:1185-94
186. Chitnis T, Khoury SJ. 2003. Role of costimulatoty pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J. Allergy Clin. Immunol. 112:837-50
187. Oliveira EM, Bar-Or A, Waliszewska AI, Cai G, Anderson DE, et al. 2003. CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. J. Autoimmun. 20:71-81
188. Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-61
189. + regulatory T cells. Int. Immunol. 16:249-56
190. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:971-79
191. Weiner HL, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A, et al. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12:809-37
192. Lafaille JJ, Keere FV, Hsu AL, Baron JL, Haas W, et al. 1997. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186:307-12
193. Wucherpfennig KW, Ota K, Endo N, Seidman JG, Rosenzweig A, et al. 1990. Shared human T cell receptor Vβ usage to immunodominant regions of myelin basic protein. Science 248:1016-19
194. Ben-Nun A, Liblau RS, Cohen L, Lehmann D, Tournier-Lasserve E, et al. 1991. Restricted T-cell receptor Vβ gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: predominant genes vary in individuals. Proc. Natl. Acad. Sci. USA 88:2466-70
195. Kotzin BL, Karuturi S, Chou YK, Lafferty J, Forrester M, et al. 1991. Preferential T-cell receptor β-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 88:9161-65
196. Afshar G, Muraro PA, McFarland HF, Martin R. 1998. Lack of over-expression of T cell receptor Vβ5.2 in myelin basic protein-specific T cell lines derived from HLA-DR2 positive multiple sclerosis patients and controls. J. Neuroimmunol. 84:7-13
197. Oksenberg JR, Stuart S, Begovich AB, Bell RB, Erlich HA, et al. 1990. Limited heterogeneity of rearranged T-cell receptor V α transcripts in brains of multiple sclerosis patients. Nature 345:344-46
198. Demoulins T, Mouthon F, Clayette P, Bequet D, Gachelin G, Dormont D. 2003. The same TCR (N)Dβ(N)Jβ junctional region is associated with several different Vβ13 subtypes in a multiple sclerosis patient at the onset of the disease. Neurobiol. Dis. 14:470-82
199. Laplaud DA, Ruiz C, Wiertlewski S, Brouard S, Berthelot L, et al. 2004. Blood T-cell receptor β chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain 127:981-95
200. Matsumoto Y, Yoon WK, Jee Y, Fujihara K, Misu T, et al. 2003. Complementarity-determining region 3 spectratyping analysis of the TCR repertoire in multiple sclerosis. J. Immunol. 170:4846-53
201. Gestri D, Baldacci L, Taiuti R, Galli E, Maggi E, et al. 2001. Oligoclonal T cell repertoire in cerebrospinal fluid of patients with inflammatory diseases of the nervous system. J. Neurol. Neurosurg. Psychiatry 70:767-72
202. Utz U, Biddison WE, McFarland HF, McFarlin DE, Flerlage M, Martin R. 1993. Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis. Nature 364:243-47
203. Haegert DG, Galutira D, Murray TJ, O'Connor P, Gadag V. 2003. Identical twins discordant for multiple sclerosis have a shift in their T-cell receptor repertoires. Clin. Exp. Immunol. 134:532-37
204. Jurewicz A, Biddison WE, Antel JP. 1998. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 160:3056-59
205. + T lymphocytes is effected through the Fas/FasL, but not the perform pathway. Eur. J. Immunol. 30:3623-33
206. + T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. USA 101:2428-33
207. Cabarrocas J, Bauer J, Piaggio E, Liblau R, Lassmann H. 2003. Effective and selective immune surveillance of the brain by MHC class I-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 33:1174-82
208. Neumann H. 2003. Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr. Opin. Neurol. 16:267-73
209. + T-cell responses to human myelin protein-derived peptides. Proc. Natl. Acad. Sci. USA 91:10859-63
210. + cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism. J. Neuroimmunol. 73:7-14
211. + cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 172:5120-27
212. + myelin peptide-specific T cells: importance of IFN-inducible protein 10. J. Immunol. 160:444-48
213. + T cells are correlated to MRI features of tissue destruction in MS. J. Neuroimmunol. 142:141-48
214. Kabat EA, Freedman DA, Murray JP, Knaub V. 1950. A study of the cristalline albumin, gamma globulin and total protein in the cerebrospinal fluid of one hundred cases of multiple sclerosis and in other diseases. Am. J. Med. Sci. 219:55-64
215. H genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102:1045-50
216. Owens GP, Kraus H, Burgoon MP, Smith-Jensen T, Devlin ME, Gilden DH. 1998. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann. Neurol. 43:236-43
217. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. 1999. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 163:5133-44
218. Walsh MJ, Tourtellotte WW. 1986. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J. Exp. Med. 163:41-53
219. Sharief MK, Thompson EJ. 1991. Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain 114(Part 1A):181-95
220. Wang LY, Fujinami RS. 1997. Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein. J. Neuroimmunol. 75:75-83
221. Wucherpfennig KW, Catz I, Hausmann S, Strominger JL, Steinman L, Warren KG. 1997. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J. Clin. Invest. 100:1114-22
222. Lou YH, Park KK, Agersborg S, Alard P, Tung KS. 2000. Retargeting T cell-mediated inflammation: a new perspective on autoantibody action. J. Immunol. 164:5251-57
223. Bornstein MB, Appel SH. 1959. Demyelination in cultures of rat cerebellum produced by experimental allergic encephalomyelitic serum. Trans. Am. Neurol. Assoc. 84:165-66
224. Esiri MM. 1977. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 2:478
225. Mattson DH, Roos RP, Arnason BG. 1980. Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature 287:335-37
226. Genain CP, Cannella B, Hauser SL, Raine CS. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:170-75
227. Trotter J, DeJong LJ, Smith ME. 1986. Opsonization with antimyelin antibody increases the uptake and intracellular metabolism of myelin in inflammatory macrophages. J. Neurochem. 47:779-89
228. Goldenberg PZ, Kwon EE, Benjamins JA, Whitaker JN, Quarles RH, Prineas JW. 1989. Opsonization of normal myelin by anti-myelin antibodies and normal serum. J. Neuroimmunol. 23:157-66
229. van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Dopp EA, Dijkstra CD. 1996. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: Phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-α and nitric oxide. J. Neuroimmunol. 70:145-52
230. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. 2002. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 168:458-65
231. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. 1998. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43:465-71
232. Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. 1998. Intrathecal activation of the complement system and disability in multiple sclerosis. J. Neurol. Sci. 157:168-74
233. Scolding NJ, Morgan BP, Houston WA, Linington C, Campbell AK, Compston DA. 1989. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339:620-22
234. Trotter JL, Rust RS. 1989. Human Cerebrospinal Fluid Immunology, ed. RM Herndon, RA Brumback, pp. 179-226. Amsterdam: Martinus Nyhoff
235. Sindic CJ, Monteyne P, Laterre EC. 1994. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J. Neuroimmunol. 54:75-80
236. Archelos JJ, Storch MK, Hartung HP. 2000. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47:694-706
237. Cross AH, Trotter JL, Lyons J. 2001. B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol. 112:1-14
238. Dharmasaroja P. 2003. Specificity of autoantibodies to epitopes of myelin proteins in multiple sclerosis. J. Neurol. Sci. 206:7-16
239. Warren KG, Catz I. 1993. Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis. J. Neuroimmunol. 43:87-96
240. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, et al. 1999. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 122(Part 11):2047-56
241. Cortese I, Tafi R, Grimaldi LM, Martino G, Nicosia A, Cortese R. 1996. Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage libraries. Proc. Natl. Acad. Sci. USA 93:11063-67
242. O'Connor KC, Chitnis T, Griffin DE, Piyasirisilp S, Bar-Or A, et al. 2003. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J. Neuroimmunol. 136:140-48
243. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, et al. 1991. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur. J. Immunol. 21:1461-68
244. Warren KG, Catz I, Johnson E, Mielke B. 1994. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann. Neurol. 35:280-89
245. Schluesener HJ, Sobel RA, Linington C, Weiner HL. 1987. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J. Immunol. 139:4016-21
246. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. 1988. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130:443-54
247. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, et al. 1998. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 8:681-94
248. Litzenburger T, Fassler R, Bauer J, Lassmann H, Linington C, et al. 1998. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J. Exp. Med. 188:169-80
249. Genain CP, Nguyen MH, Letvin NL, Pearl R, Davis RL, et al. 1995. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 96:2966-74
250. Sun J, Link H, Olsson T, Xiao BG, Andersson G, et al. 1991. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J. Immunol. 146:1490-95
251. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, et al. 2003. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 349:139-45
252. Lily O, Palace J, Vincent A. 2004. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 127:269-79
253. Robinson WH, Fontoura P, Lee BJ, de Vegvar HE, Tom J, et al. 2003. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 21:1033-39
254. Saoudi A, Simmonds S, Huitinga I, Mason D. 1995. Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells. J. Exp. Med. 182:335-44
255. Rodriguez M, Lennon VA. 1990. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 27:12-17
256. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, et al. 1998. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398-402
257. Sewell WA, Jolles S. 2002. Immunomodulatory action of intravenous immunoglobulin. Immunology 107:387-93
258. van Kooyk Y, Geijtenbeek TB. 2002. A novel adhesion pathway that regulates dendritic cell trafficking and T cell interactions. Immunol. Rev. 186:47-56
259. + T cell-mediated suppression by dendritic cells. Science 299:1033-36
260. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, et al. 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. USA 95:8222-26
261. Hawiger D, Inaba K, Dorsett Y, Quo M, Mahnke K, et al. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194:769-79
262. Tsunoda I, Tolley ND, Theil DJ, Whitton JL, Kobayashi H, Fujinami RS. 1999. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol. 9:481-93
263. Ichikawa HT, Williams LP, Segal BM. 2002. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169:2781-87
264. Zappulla JP, Arock M, Mars LT, Liblau RS. 2002. Mast cells: new targets for multiple sclerosis therapy? J. Neuroimmunol. 131:5-20
265. Neumann J. 1890. Über das Vorkommen der sogenannten "Mastzellen" bei pathologischen Veränderungen des Gehirns. Virchow's Arch. Pathol. Anat. 122:378-80
266. Kruger PG. 2001. Mast cells and multiple sclerosis: a quantitative analysis. Neuropathol. Appl. Neurobiol. 27:275-80
267. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, et al. 1994. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36:778-86
268. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. 1993. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151:2132-41
269. Mitrovic B, Ignarro LJ, Vinters HV, Akers MA, Schmid I, et al. 1995. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience 65:531-39
270. Benczur M, Petranyl GG, Palffy G, Varga M, Talas M, et al. 1980. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin. Exp. Immunol. 39:657-62
271. Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, et al. 1998. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J. Neuroimmunol. 86:123-33
272. Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, Paty DW. 2003. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J. Neuroimmunol. 145:103-14
273. Munschauer FE, Hartrich LA, Stewart CC, Jacobs L. 1995. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J. Neuroimmunol. 62:177-81
274. Weber WE, Buurman WA, Vandertneeren MM, Medaer RH, Raus JC. 1987. Fine analysis of cytolytic and natural killer T lymphocytes in the CSF in multiple sclerosis and other neurologic diseases. Neurology 37:419-25
275. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. 1997. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186:1677-87
276. Matsumoto Y, Kohyama K, Aikawa Y, Shin T, Kawazoe Y, et al. 1998. Role of natural killer cells and TCR γδ T cells in acute autoimmune encephalomyelitis. Eur. J. Immunol. 28:1681-88
277. Smeltz RB, Wolf NA, Swanborg RH. 1999. Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J. Immunol. 163:1390-97
278. Peng SL, Moslehi J, Robert ME, Craft J. 1998. Perform protects against autoimmunity in lupus-prone mice. J. Immunol. 160:652-60
279. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. 2001. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encphalomyelitis. J. Immunol. 166:1314-19
280. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, et al. 2004. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc. Natl. Acad. Sci. USA 101:8705-8
281. Vanguri P, Shin ML. 1986. Activation of complement by myelin: identification of C1-binding proteins of human myelin from central nervous tissue. J. Neurochem. 46:1535-41
282. Scolding NJ, Morgan BP, Houston A, Campbell AK, Linington C, Compston DA. 1989. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies. J. Neurol. Sci. 89:289-300
283. Johns TG, Bernard CC. 1997. Binding of complement component Clq to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol. Immunol. 34:33-38
284. Piddlesden SJ, Morgan BP. 1993. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J. Neuroimmunol. 48:169-75
285. Park SH, Bendelac A. 2000. CD1-restricted T-cell responses and microbial infection. Nature 406:788-92
286. Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. 2000. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164:4375-81
287. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100:144-48
288. - Vα24JαQ T cells in peripheral blood of patients with relapsing-remitting multiple sclerosis. Clin. Immunol. 98:11-17
289. Miyamoto K, Miyake S, Yamamura T. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413:531-34
290. Triebel F, Hercend T. 1989. Subpopulations of human peripheral T γδ lymphocytes. Immunol. Today 10:186-88
291. Battistini L, Salvetti M, Ristori G, Falcone M, Raine CS, Brosnan CF. 1995. γδ T cell receptor analysis supports a role for HSP 70 selection of lymphocytes in multiple sclerosis lesions. Mol. Med. 1:554-62
292. Freedman MS, Bitar R, Antel JP. 1997. γδ T-cell-human glial cell interactions. II. Relationship between heat shock protein expression and susceptibility to cytolysis. J. Neuroimmunol. 74:143-48
293. Nick S, Pileri P, Tongiani S, Uematsu Y, Kappos L, De Libero G. 1995. T cell receptor γδ repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen-reactive γδ clones. Eur. J. Immunol. 25:355-63
294. Stinissen P, Vandevyver C, Medaer R, Vandegaer L, Nies J, et al. 1995. Increased frequency of γδ T cells in cerebrospinal fluid and peripheral blood of patients with multiple sclerosis. Reactivity, cytotoxicity, and T cell receptor V gene rearrangements. J. Immunol. 154:4883-94
295. Birnbaum G, Kotilinek L, Albrecht L. 1993. Spinal fluid lymphocytes from a subgroup of multiple sclerosis patients respond to mycobacterial antigens. Ann. Neurol. 34:18-24
296. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, et al. 1994. Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science 264:267-70
297. Rajan AJ, Gao YL, Raine CS, Brosnan CF. 1996. A pathogenic role for γδ T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse. J. Immunol. 157:941-49
298. Bielekova B, Martin R. 2004. Development of biomarkers in multiple sclerosis. Brain 127:1463-78
299. Navikas V, He B, Link J, Haglund M, Soderstrom M, et al. 1996. Augmented expression of tumour necrosis factor-α and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain 119(Part 1):213-23
300. Hohnoki K, Inoue A, Koh CS. 1998. Elevated serum levels of IFN-γ, IL-4 and TNF-α/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J. Neuroimmunol. 87:27-32
301. Ozenci V, Kouwenhoven M, Huang YM, Kivisakk P, Link H. 2000. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-α (TNF-α)- and IL-10-secreting blood cells that is corrected by interferon-β (IFN-β) treatment. Clin. Exp. Immunol. 120:147-53
302. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457-65
303. Nguyen LT, Ramanathan M, Munschauer F, Brownscheidle C, Krantz S, et al. 1999. Flow cytometric analysis of in vitro proinflammatory cytokine secretion in peripheral blood from multiple sclerosis patients. J. Clin. Immunol. 19:179-85
304. Panitch HS, Hirsch RL, Schindler J, Johnson KP. 1987. Treatment of multiple sclerosis with γ interferon: exacerbations associated with activation of the immune system. Neurology 37:1097-102
305. Segal BM, Dwyer BK, Shevach EM. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187:537-46
306. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744-48
307. Matusevicius D, Kivisakk P, Navikas V, Soderstrom M, Fredrikson S, Link H. 1998. Interleukin-12 and perform mRNA expression is augmented in blood mononuclear cells in multiple sclerosis. Scand. J. Immunol. 47:582-90
308. Heesen C, Sieverding F, Schoser BG, Hadji B, Kunze K. 1999. Interleukin-12 is detectable in sera of patients with multiple sclerosis-association with chronic progressive disease course? Eur. J. Neurol. 6:591-96
309. Huang WX, Huang P, Link H, Hillert J. 1999. Cytokine analysis in multiple sclerosis by competitive RT-PCR: a decreased expression of IL-10 and an increased expression of TNF-α in chronic progression. Mult. Scler. 5:342-48
310. Navikas V, Link J, Palasik W, Soderstrom M, Fredrikson S, et al. 1995. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand. J. Immunol. 41:171-78
311. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, et al. 1995. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182:1985-96
312. Cannella B, Raine CS. 1995. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:424-35
313. Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Bruck W. 2000. Tumour necrosis factor α mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 29:366-75
314. Owens T, Wekerle H, Antel J. 2001. Genetic models for CNS inflammation. Nat. Med. 7:161-66
315. Pouly S, Becher B, Blain M, Antel JP. 2000. Interferon-γ modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J. Neuropathol. Exp. Neurol. 59:280-86
316. Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H. 1994. Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann. Neurol. 36:379-86
317. Nakashima I, Fujihara K, Misu T, Okita N, Takase S, Itoyama Y. 2000. Significant correlation between IL-10 levels and IgG indices in the cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 111:64-67
318. Issazadeh S, Mustafa M, Ljungdahl Å, Höjeberg B, Dagerlind Å, et al. 1995. Interferon-γ, interleukin-4 and transforming growth factor β in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J. Neurosci. Res. 40:579-90
319. Sindern E. 2004. Role of chemokines and their receptors in the pathogenesis of multiple sclerosis. Front Biosci. 9:457-63
320. Trebst C, Ransohoff RM. 2001. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch. Neurol. 58:1975-80
321. Calabresi PA, Martin R, Jacobson S. 1999. Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis. J. Neurovirol. 5:102-8
322. + interferon-γ- and tumor necrosis factor-α-secreting T lymphocytes in multiple sclerosis patients. Ann. Neurol. 47:269-73
323. Misu T, Onodera H, Fujihara K, Matsushima K, Yoshie O, et al. 2001. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J. Neuroimmunol. 114:207-12
324. + T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA 96:6873-78
325. Calabresi PA, Yun SH, Allie R, Whartenby KA. 2002. Chemokine receptor expression on MBP-reactive T cells: CXCR6 is a marker of IFNγ-producing effector cells. J. Neuroimmunol. 127:96-105
326. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, et al. 1999. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:807-15
327. Sorensen TL, Sellebjerg F, Jensen CV, Stricter RM, Ransohoff RM. 2001. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur. J. Neurol. 8:665-72
328. Sindern E, Niederkinkhaus Y, Henschel M, Ossege LM, Patzold T, Malin JP. 2001. Differential release of β-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol. Scand. 104:88-91
329. Kivisakk P, Trebst C, Liu Z, Tucky BH, Sorensen TL, et al. 2002. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin. Exp. Immunol. 129:510-18
330. Giunti D, Borsellino G, Benelli R, Marchese M, Capello E, et al. 2003. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J. Leukoc. Biol. 73:584-90
331. + mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol 159:1701-10
332. Boven LA, Montagne L, Nottet HS, De Groot CJ. 2000. Macrophage inflammatory protein-1α (MIP-1α), MIP-1β, and RANTES mRNA semiquantiflcation and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin. Exp. Immunol. 122:257-63
333. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN. 2000. Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J. Neuroimmunol. 108:192-200
334. Elhofy A, Kennedy KJ, Fife BT, Karpus WJ. 2002. Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors. Immunol. Res. 25:167-75
335. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. 2000. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 192:899-905
336. Rottman JB, Slavin AJ, Silva R, Weiner HL, Gerard CG, Hancock WW. 2000. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur. J. Immunol. 30:2372-77
337. Tran EH, Kuziel WA, Owens T. 2000. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1α or its CCR5 receptor. Eur. J. Immunol. 30:1410-15
338. Flugel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, et al. 2001. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14:547-60
339. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. 1998. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:278-85
340. Karnezis T, Mandemakers W, McQualter JL, Zheng B, Ho PP, et al. 2004. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat. Neurosci. 7:736-44
341. Whitaker JN, Kirk KA, Herman PK, Zhou SR, Goodin RR, et al. 1992. An immunochemical comparison of human myelin basic protein and its modified, citrullinated form, C8. J. Neuroimmunol. 36:135-46
342. Wood DD, Bilbao JM, O'Connors P, Moscarello MA. 1996. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann. Neurol. 40:18-24
343. Bruck W, Lucchinetti C, Lassmann H. 2002. The pathology of primary progressive multiple sclerosis. Mult. Scler. 8:93-97
344. Werner P, Pitt D, Raine CS. 2001. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 50:169-80
345. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45:1268-76
346. Arnon R. 1996. The development of Cop1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol. Lett. 50:1-15
347. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. 2002. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125:2381-91
348. Chen M, Valenzuela RM, Dhib-Jalbut S. 2003. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J. Neurol. Sci. 215:37-44
349. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, et al. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15-23
350. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, et al. 1999. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46:296-304
351. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, et al. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84
352. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, et al. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-8
353. Weber F, Polak T, Gunther A, Kubuschok B, Janovskaja J, et al. 1998. Synergistic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann. Neurol. 44:27-34
354. Zhang JZ, Rivera VM, Tejada-Simon MV, Yang DY, Hong J, et al. 2002. T cell vaccination in multiple sclerosis: results of a preliminary study. J. Neurol. 249:212-18
355. Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, et al. 1996. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. 2:1109-15
356. + T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann. Neurol. 51:467-74
357. Mancardi GL, Saccardi R, Filippi M, Gualandi F, Murialdo A, et al. 2001. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57:62-68
358. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, et al. 2003. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102:2373-78
359. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, et al. 2003. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102:2364-72